{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:07Z","timestamp":1792691767019,"version":"4.5.0"},"reference-count":215,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006701","name":"Umm Al-Qura University","doi-asserted-by":"publisher","award":["26UQU4331174GSSR03"],"award-info":[{"award-number":["26UQU4331174GSSR03"]}],"id":[{"id":"10.13039\/501100006701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110048","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T15:16:03Z","timestamp":1780067763000},"page":"110048","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies"],"prefix":"10.1016","volume":"180","author":[{"given":"Eman","family":"M. Elkafoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahenda","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Afarinkia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.M.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf K.","family":"El-Damasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharaf Ezzat","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman R.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Jaragh-Alhadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Sidhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110048_bb0005","doi-asserted-by":"crossref","first-page":"1576781","DOI":"10.3389\/fonc.2025.1576781","article-title":"Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation","volume":"15","author":"Tian","year":"2025","journal-title":"Front. Oncol."},{"issue":"41","key":"10.1016\/j.bioorg.2026.110048_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202507904","article-title":"Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-DeficiENT TUMOR","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70314","article-title":"PARP (Poly ADP-ribose Polymerase) Family in Health and Disease","volume":"6","author":"Lei","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.bioorg.2026.110048_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103000","article-title":"The emerging role of PARP inhibitors in prostate cancer: a narrative review","author":"Lobianco","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13046-025-03335-5","article-title":"CD47 blockade reverses resistance to HDAC inhibitor by liberating anti-tumor capacity of macrophages","volume":"44","author":"Xu","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ijc.34027","article-title":"A synergistic interaction between HDAC-and PARP inhibitors in childhood tumors with chromothripsis","volume":"151","author":"Khalid","year":"2022","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110048_bb0045","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.2147\/OTT.S119428","article-title":"BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy","author":"Chowdhary","year":"2016","journal-title":"Onco. Targets Ther."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0050","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1021\/jacs.4c11930","article-title":"A dual-target and dual-mechanism design strategy by combining inhibition and degradation together","volume":"147","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0055","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1021\/cr5004248","article-title":"New facets in the regulation of gene expression by ADP-ribosylation and poly (ADP-ribose) polymerases","volume":"115","author":"Ryu","year":"2015","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0060","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2174\/138161207780414241","article-title":"Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications","volume":"13","author":"de la Lastra","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"Pt 10","key":"10.1016\/j.bioorg.2026.110048_bb0065","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1107\/S1399004714017660","article-title":"Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2","volume":"70","author":"Qiu","year":"2014","journal-title":"Acta Crystall. D Biol. Crystall."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrm3376","article-title":"New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs","volume":"13","author":"Gibson","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1101\/gad.183509.111","article-title":"On PAR with PARP: cellular stress signaling through poly (ADP-ribose) and PARP-1","volume":"26","author":"Luo","year":"2012","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0085","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cells8091047","article-title":"The role of PARPs in inflammation\u2014and metabolic\u2014related diseases: molecular mechanisms and beyond","volume":"8","author":"Ke","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0090","doi-asserted-by":"crossref","first-page":"eadm6812","DOI":"10.1126\/sciadv.adm6812","article-title":"Zinc-finger PARP proteins ADP-ribosylate alphaviral proteins and are required for interferon-\u03b3-mediated antiviral immunity","volume":"11","author":"Ryan","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2026.110048_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116803","article-title":"Parps in immune response: Potential targets for cancer immunotherapy","volume":"234","author":"Wang","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0100","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114002","article-title":"Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors","volume":"13","author":"Angers","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0105","first-page":"201","article-title":"Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited","volume":"1846","author":"Lupo","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb0110","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/era.10.53","article-title":"Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy","volume":"10","author":"Heitz","year":"2010","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.bioorg.2026.110048_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107924","article-title":"Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition","volume":"153","author":"Elkafoury","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"12_Supplement","key":"10.1016\/j.bioorg.2026.110048_bb0120","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1538-7445.AM2022-6302","article-title":"Structure-based and property-based drug design of AZD9574, a CNS penetrant PARP1 selective inhibitor and trapper","volume":"82","author":"Ghosh","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","article-title":"PARP7 as a new target for activating anti-tumor immunity in cancer","volume":"17","author":"Popova","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bioorg.2026.110048_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118743","article-title":"InhibitWin duo: Rational design and structural insights into dual PARP\/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation","author":"Elkafoury","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0140","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.3390\/cancers17244011","article-title":"Targeting MARylation and DePARylation in Cancer Therapy: New Promising Therapeutic Opportunities","volume":"17","author":"Cabeza-Fern\u00e1ndez","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110048_bb0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly (ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0150","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0006-291X(66)90502-X","article-title":"On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei","volume":"25","author":"Chambon","year":"1966","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2026.110048_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102078","article-title":"Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: Past, present, and future","volume":"91","author":"Hu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.bioorg.2026.110048_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","article-title":"The comings and goings of PARP-1 in response to DNA damage","volume":"71","author":"Pascal","year":"2018","journal-title":"DNA Repair (Amst)"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0165","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","article-title":"Rapid Detection and Signaling of DNA Damage by PARP-1","volume":"46","author":"Pandey","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"7035","key":"10.1016\/j.bioorg.2026.110048_bb0170","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110048_bb0175","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1016\/S0021-9258(18)95947-8","article-title":"Studies on the Polymer of Adenosine Diphosphate Ribose: I. ENZYMIC FORMATION FROM NICOTINAMIDE ADENINE DINUCLEOTIDE IN MAMMALIAN NUCLEI","volume":"242","author":"Nishizuka","year":"1967","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0180","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0003-9861(71)90164-0","article-title":"Studies on poly (adenosine diphosphate-ribose): X. Properties of a partially purified poly (adenosine diphosphate-ribose) polymerase","volume":"146","author":"Yamada","year":"1971","journal-title":"Arch. Biochem. Biophys."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110048_bb0185","doi-asserted-by":"crossref","first-page":"10493","DOI":"10.1016\/S0021-9258(19)70490-6","article-title":"ADP-ribosylation in mammalian cell ghosts. Dependence of poly (ADP-ribose) synthesis on strand breakage in DNA","volume":"255","author":"Benjamin","year":"1980","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0190","first-page":"107","article-title":"Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly (ADP-ribose) polymerase","volume":"6","author":"Suto","year":"1991","journal-title":"Anticancer Drug Des."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2307\/3577927","article-title":"Effects of PD 128763, a new potent inhibitor of poly (ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in chinese hamster V79 Cells","volume":"126","author":"Arundel-Suto","year":"1991","journal-title":"Radiat. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0200","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0021-9258(18)45983-2","article-title":"Specific inhibitors of poly (ADP-ribose) synthetase and mono (ADP-ribosyl) transferase","volume":"267","author":"Banasik","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0205","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1042\/bj1850775","article-title":"Novel inhibitors of poly (ADP-ribose) synthetase","volume":"185","author":"Purnell","year":"1980","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0006-291X(68)90486-5","article-title":"Poly adenosine diphosphate ribose synthesis associated with chromatin","volume":"31","author":"Ueda","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0215","first-page":"145","article-title":"Binding of ADP-ribose polymer with histone","volume":"65","author":"Otake","year":"1969","journal-title":"J. Biochem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0220","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1101\/gad.9.5.509","article-title":"Mice lacking ADPRT and poly (ADP-ribosyl) ation develop normally but are susceptible to skin disease","volume":"9","author":"Wang","year":"1995","journal-title":"Genes Dev."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110048_bb0225","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1073\/pnas.93.15.7481","article-title":"Structure of the catalytic fragment of poly (AD-ribose) polymerase from chicken","volume":"93","author":"Ruf","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"25","key":"10.1016\/j.bioorg.2026.110048_bb0230","doi-asserted-by":"crossref","first-page":"17860","DOI":"10.1074\/jbc.274.25.17860","article-title":"PARP-2, A novel mammalian DNA damage-dependent poly (ADP-ribose) polymerase","volume":"274","author":"Am\u00e9","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0235","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/emboj\/cdg206","article-title":"Functional interaction between PARP\u20101 and PARP\u20102 in chromosome stability and embryonic development in mouse","volume":"22","author":"M\u00e9nissier de Murcia","year":"2003","journal-title":"The EMBO journal"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb0240","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly (ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110048_bb0245","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1021\/jm0502891","article-title":"Discovery of potent poly (ADP-ribose) polymerase-1 inhibitors from the modification of indeno [1, 2-c] isoquinolinone","volume":"48","author":"Jagtap","year":"2005","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0250","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110048_bb0255","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 H-phthalazin-1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0260","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","article-title":"PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation","volume":"13","author":"Bai","year":"2011","journal-title":"Cell Metab."},{"issue":"6082","key":"10.1016\/j.bioorg.2026.110048_bb0265","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1216338","article-title":"Structural basis for DNA damage\u2013dependent poly (ADP-ribosyl) ation by human PARP-1","volume":"336","author":"Langelier","year":"2012","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0270","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1038\/ncomms5426","article-title":"Family-wide analysis of poly (ADP-ribose) polymerase activity","volume":"5","author":"Vyas","year":"2014","journal-title":"Nat. Commun."},{"issue":"6290","key":"10.1016\/j.bioorg.2026.110048_bb0275","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.aad9335","article-title":"ADP-ribose\u2013derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling","volume":"352","author":"Wright","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110048_bb0280","series-title":"New Research on Cell Aging and Death","first-page":"131","article-title":"Nicotinamide adenine dinucleotide (NAD+) and cell aging","author":"Takihara","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110048_bb0285","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-cancerbio-030518-055914","article-title":"PARP trapping beyond homologous recombination and platinum sensitivity in cancers","volume":"3","author":"Murai","year":"2019","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0290","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1038\/s41467-020-19961-w","article-title":"Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens","volume":"11","author":"Clements","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0295","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-021-23003-4","article-title":"Identification of poly (ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells","volume":"12","author":"Xing","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb0300","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1093\/nar\/gkac119","article-title":"Polymerase theta-helicase promotes end joining by stripping single-stranded DNA-binding proteins and bridging DNA ends","volume":"50","author":"Schaub","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110048_bb0305","series-title":"Targeting the DNA Damage Response for Cancer Therapy","first-page":"143","article-title":"Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges","author":"Thein","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110048_bb0310","series-title":"Overexpression of ABCC1 and ABCG2 Confers Resistance to BMN-673, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitors","author":"Teng","year":"2023"},{"key":"10.1016\/j.bioorg.2026.110048_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101028","article-title":"Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor","volume":"73","author":"Teng","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.bioorg.2026.110048_bb0320","doi-asserted-by":"crossref","first-page":"1525736","DOI":"10.3389\/fimmu.2025.1525736","article-title":"cGAS\/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110048_bb0325","doi-asserted-by":"crossref","first-page":"1537615","DOI":"10.3389\/fimmu.2025.1537615","article-title":"PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy","volume":"16","author":"Matsumoto","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110048_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2024.103690","article-title":"The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication","volume":"140","author":"Zhang","year":"2024","journal-title":"DNA Repair"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105779","article-title":"Dynamics of endogenous PARP1 and PARP2 during DNA damage revealed by live-cell single-molecule imaging","volume":"26","author":"Mahadevan","year":"2023","journal-title":"IScience"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0340","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA damage repair pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics, Proteomics & Bioinformatics"},{"key":"10.1016\/j.bioorg.2026.110048_bb0345","series-title":"Practical Guide to Hereditary Breast and Ovarian Cancer III: Annual Meeting of the Japanese Organization of Hereditary Breast and Ovarian Cancer 2023","first-page":"17","article-title":"Mechanisms Underlying the Resistance","author":"Taniguchi","year":"2025"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0350","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/2767-9764.CRC-24-0111","article-title":"BRCA status dictates Wnt responsiveness in epithelial ovarian cancer","volume":"4","author":"Chehade","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"09","key":"10.1016\/j.bioorg.2026.110048_bb0355","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1055\/a-2181-0813","article-title":"A review of PARP-1 inhibitors: assessing emerging prospects and tailoring therapeutic strategies","volume":"73","author":"Ramesh","year":"2023","journal-title":"Drug Res.earch"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0360","first-page":"521","article-title":"Development of next-generation poly (ADP-ribose) polymerase 1\u2013selective inhibitors","volume":"27","author":"Ngoi","year":"2021","journal-title":"Can. J."},{"key":"10.1016\/j.bioorg.2026.110048_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103385","article-title":"Design, synthesis and biological evaluation of homoerythrina alkaloid derivatives bearing a triazole moiety as PARP-1 inhibitors and as potential antitumor drugs","volume":"94","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103575","article-title":"Design, synthesis and biological evaluation of erythrina derivatives bearing a 1, 2, 3-triazole moiety as PARP-1 inhibitors","volume":"96","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110048_bb0375","doi-asserted-by":"crossref","first-page":"12089","DOI":"10.1021\/acs.jmedchem.1c00735","article-title":"Discovery of novel apigenin\u2013piperazine hybrids as potent and selective poly (ADP-Ribose) polymerase-1 (PARP-1) inhibitors for the treatment of cancer","volume":"64","author":"Long","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0380","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/molecules27030703","article-title":"Design and activity of novel oxadiazole based compounds that target poly (ADP-ribose) polymerase","volume":"27","author":"Vishwanath","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0385","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s00044-020-02537-0","article-title":"Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia","volume":"29","author":"Hewlett","year":"2020","journal-title":"Med. Chem. Res."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110048_bb0390","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1080\/17568919.2025.2561467","article-title":"Design, development, and therapeutic applications of PARP-1 selective inhibitors","volume":"17","author":"Xu","year":"2025","journal-title":"Future Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0395","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0400","series-title":"Metalloenzymes","first-page":"265","article-title":"Histone deacetylases and other epigenetic targets","author":"Carta","year":"2024"},{"issue":"19","key":"10.1016\/j.bioorg.2026.110048_bb0405","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.2174\/1389557522666220330144151","article-title":"The Zinc-dependent HDACs: Non-histone substrates and catalytic deacylation beyond deacetylation","volume":"22","author":"Zheng","year":"2022","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0410","first-page":"1","article-title":"Epidrugs in cancer: mechanisms, applications, and future direction","author":"Bibi","year":"2025","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0415","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00425-024-04518-8","article-title":"Advances in understanding the roles of plant HAT and HDAC in non-histone protein acetylation and deacetylation","volume":"260","author":"Zhang","year":"2024","journal-title":"Planta"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0420","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/cells11050863","article-title":"Insights into the histone acetylation-mediated regulation of the transcription factor genes that control the embryogenic transition in the somatic cells of Arabidopsis","volume":"11","author":"Moro\u0144czyk","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110048_bb0425","doi-asserted-by":"crossref","first-page":"1900043","DOI":"10.1002\/bies.201900043","article-title":"Regulation of Gene Expression and Replication Initiation by Non-Coding Transcription: A Model Based on Reshaping Nucleosome-Depleted Regions","volume":"41","author":"Stutz","year":"2019","journal-title":"BioEssays"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0430","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cclet.2019.04.045","article-title":"Synthesis and biological evaluation of piperidyl benzimidazole carboxamide derivatives as potent PARP-1 inhibitors and antitumor agents","volume":"31","author":"Zhang","year":"2020","journal-title":"Chin. Chem. Lett."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0435","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cclet.2019.06.019","article-title":"Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents","volume":"31","author":"Dai","year":"2020","journal-title":"Chin. Chem. Lett."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110048_bb0440","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4155\/fmc-2020-0009","article-title":"Design and synthesis of novel phthalazinone derivatives as potent poly(ADP-ribose)polymerase 1 inhibitors","volume":"12","author":"Xin","year":"2020","journal-title":"Future Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127036","article-title":"Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1\/histone deacetylase-1 inhibitors","volume":"30","author":"Tian","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115434","article-title":"Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities","volume":"28","author":"Lin","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128169","article-title":"Design, synthesis and biological evaluation of novel molecules as potent PARP-1 inhibitors","volume":"47","author":"Shen","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110048_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127710","article-title":"Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors","volume":"31","author":"Xiang","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110048_bb0465","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/acs.jmedchem.1c00932","article-title":"Discovery of a Dual Tubulin and Poly(ADP-Ribose) Polymerase-1 Inhibitor by Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, and Biological Evaluation","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0470","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/bs.ai.2020.06.002","article-title":"The role of NK cell as central communicators in cancer immunity","volume":"147","author":"Bald","year":"2020","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0475","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/genes11050556","article-title":"Histone deacetylases (HDACs): evolution, specificity, role in transcriptional complexes, and pharmacological actionability","volume":"11","author":"Milazzo","year":"2020","journal-title":"Genes"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110048_bb0480","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s00018-012-0921-9","article-title":"Multiple roles of class I HDACs in proliferation, differentiation, and development","volume":"69","author":"Reichert","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0485","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/febs.13061","article-title":"Class II a HDAC s\u2013new insights into their functions in physiology and pathology","volume":"282","author":"Parra","year":"2015","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0490","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/epi.15.106","article-title":"Regulation of class IIa HDAC activities: it is not only matter of subcellular localization","volume":"8","author":"Di Giorgio","year":"2016","journal-title":"Epigenomics"},{"issue":"23","key":"10.1016\/j.bioorg.2026.110048_bb0495","doi-asserted-by":"crossref","first-page":"21223","DOI":"10.1021\/acs.jmedchem.4c02024","article-title":"Deciphering the therapeutic potential of novel pentyloxyamide-based class I, IIb HDAC inhibitors against therapy-resistant leukemia","volume":"67","author":"Fischer","year":"2024","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0500","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/s40001-025-02840-9","article-title":"The role of HDAC6 in fibrosis: a novel and effective therapy strategy","volume":"30","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijmm.2025.5578","article-title":"Histone deacetylase 6: A new player in oxidative stress-associated disorders and cancers","volume":"56","author":"Qu","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0510","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/hearts5010005","article-title":"Different mechanisms in doxorubicin-induced cardiomyopathy: impact of BRCA1 and BRCA2 mutations","volume":"5","author":"Nguyen","year":"2024","journal-title":"Hearts"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0515","doi-asserted-by":"crossref","first-page":"2309824","DOI":"10.1080\/15592294.2024.2309824","article-title":"Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors","volume":"19","author":"Krushkal","year":"2024","journal-title":"Epigenetics"},{"issue":"21","key":"10.1016\/j.bioorg.2026.110048_bb0520","doi-asserted-by":"crossref","first-page":"14787","DOI":"10.1021\/acs.jmedchem.3c01385","article-title":"Development of first-in-class dual Sirt2\/HDAC6 inhibitors as molecular tools for dual inhibition of tubulin deacetylation","volume":"66","author":"Sinatra","year":"2023","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0525","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1021\/acs.accounts.3c00801","article-title":"Chemical versatility in catalysis and inhibition of the class IIb histone deacetylases","volume":"57","author":"Christianson","year":"2024","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0530","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14366","article-title":"Discussion on structure classification and regulation function of histone deacetylase and their inhibitor","volume":"103","author":"Han","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0535","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1042\/bj0870258","article-title":"The presence of acetyl groups in histones","volume":"87","author":"Phillips","year":"1963","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0540","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1073\/pnas.51.5.786","article-title":"Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis","volume":"51","author":"Allfrey","year":"1964","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5619","key":"10.1016\/j.bioorg.2026.110048_bb0545","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/268462a0","article-title":"n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells","volume":"268","author":"Riggs","year":"1977","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0550","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0092-8674(78)90305-7","article-title":"Sodium butyrate inhibits histone deacetylation in cultured cells","volume":"14","author":"Candido","year":"1978","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0555","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1073\/pnas.75.5.2239","article-title":"Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences","volume":"75","author":"Vidali","year":"1978","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2026.110048_bb0560","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/9783527800315.ch2","article-title":"Romidepsin and the Zinc-binding thiol family of natural product HDAC inhibitors","volume":"2","author":"Ganesan","year":"2016","journal-title":"Succ. Drug Discov."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0565","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0092-8674(00)81063-6","article-title":"Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation","volume":"84","author":"Brownell","year":"1996","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0570","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1021\/jm0303094","article-title":"Histone deacetylase inhibitors","volume":"46","author":"Miller","year":"2003","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110048_bb0575","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0580","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cells10010012","article-title":"HDAC6 in diseases of cognition and of neurons","volume":"10","author":"LoPresti","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0585","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/jacsau.4c01148","article-title":"Discovery of De Novo Macrocycle Inhibitors of Histone Deacetylase 11","volume":"5","author":"Dankov\u00e1","year":"2025","journal-title":"JACS Au"},{"key":"10.1016\/j.bioorg.2026.110048_bb0590","series-title":"Histone and Non-Histone Reversible Acetylation in Development, Aging and Disease","first-page":"247","article-title":"Acetylation in Cardiac Aging: Molecular Mechanism and Therapeutic Approaches","volume":"75","author":"Hase","year":"2025"},{"issue":"06","key":"10.1016\/j.bioorg.2026.110048_bb0595","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1142\/S2737416524500121","article-title":"Machine Learning Approaches to Predict the Selectivity of Compounds against HDAC1 and HDAC6","volume":"23","author":"Dogan","year":"2024","journal-title":"J. Comput. Biophys. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117998","article-title":"Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders","author":"Costanzo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0605","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1568009622666220624090542","article-title":"Recent progress in histone deacetylase (HDAC) 1 inhibitors as anticancer agent","volume":"23","author":"Patel","year":"2023","journal-title":"Curr. Cancer Drug Targets"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0610","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s13402-022-00704-6","article-title":"HDAC6: A unique HDAC family member as a cancer target","volume":"45","author":"Kaur","year":"2022","journal-title":"Cell. Oncol."},{"issue":"21","key":"10.1016\/j.bioorg.2026.110048_bb0615","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.2174\/0929867327666201111142653","article-title":"Recent development of novel HDAC6 isoform-selective Inhibitors","volume":"28","author":"Zhao","year":"2021","journal-title":"Curr. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0620","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.2174\/0929867328666210902145102","article-title":"Dual targeting strategies on histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90)","volume":"29","author":"Bonanni","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110048_bb0625","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1002\/1878-0261.12953","article-title":"Immune modulation underpins the anti-cancer activity of HDAC inhibitors","volume":"15","author":"Blaszczak","year":"2021","journal-title":"Mol. Oncol."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110048_bb0630","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.7150\/ijbs.62001","article-title":"Preclinical and clinical progress for HDAC as a putative target for epigenetic remodeling and functionality of immune cells","volume":"17","author":"Zhang","year":"2021","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0635","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/pathophysiology29030038","article-title":"Critical functions of histone deacetylases (HDACs) in modulating inflammation associated with cardiovascular diseases","volume":"29","author":"Kulthinee","year":"2022","journal-title":"Pathophysiology"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0640","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/1570159X19666210609160017","article-title":"Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: current targets and future perspective","volume":"20","author":"Kumar","year":"2022","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0645","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s12013-024-01587-0","article-title":"Histone deacetylases (HDACs) roles in inflammation-mediated diseases; current knowledge","volume":"83","author":"Jasim","year":"2025","journal-title":"Cell Biochem. Biophys."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0650","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1002\/ptr.70044","article-title":"The Combination of Natural Products: A Promising Therapeutical Way for Management of Breast Cancers","volume":"39","author":"Wang","year":"2025","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bioorg.2026.110048_bb0655","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932914","article-title":"Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment","volume":"13","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0660","article-title":"Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors","volume":"17","author":"Sch\u00e4ker-H\u00fcbner","year":"2022","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110048_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130312","article-title":"Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors","author":"Lowe","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110048_bb0670","doi-asserted-by":"crossref","DOI":"10.1111\/febs.70062","article-title":"Pharmacological manipulation of liver fibrosis progression using novel HDAC 6 inhibitors","author":"Borrello","year":"2025","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0675","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/med.20056","article-title":"Targeting histone deacetylase in cancer therapy","volume":"26","author":"Lin","year":"2006","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0680","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2174\/138945012802008973","article-title":"Discovery and mechanism of natural products as modulators of histone acetylation","volume":"13","author":"Salvador","year":"2012","journal-title":"Curr. Drug Targets"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/cells14241997","article-title":"Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy","volume":"14","author":"Hawash","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110048_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128797","article-title":"Comparison of three zinc binding groups for HDAC inhibitors \u2013 A potency, selectivity and enzymatic kinetics study","volume":"70","author":"Yue","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0695","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13065-025-01389-2","article-title":"Multi-stage structure-based virtual screening approach combining 3D pharmacophore, docking and molecular dynamic simulation towards the identification of potential selective PARP-1 inhibitors","volume":"19","author":"El Hassab","year":"2025","journal-title":"BMC Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0700","doi-asserted-by":"crossref","first-page":"2300599","DOI":"10.1002\/ardp.202300599","article-title":"Phthalimide-tethered isatins as novel poly (ADP-ribose) polymerase inhibitors: design, synthesis, biological evaluations, and molecular modeling investigations","volume":"357","author":"El Hassab","year":"2024","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2026.110048_bb0705","first-page":"1","article-title":"Pharmacophore modeling, 3D-QSAR, and MD simulation-based overture for the discovery of new potential HDAC1 inhibitors","author":"Lanka","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.110048_bb0710","first-page":"1","article-title":"Repurposing of DrugBank molecules as dual non-hydroxamate HDAC8 and HDAC2 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics studies","author":"Sarkar","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0715","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110048_bb0720","series-title":"Histone Deacetylase Inhibition Increases the Radiosensitivity of HPV-Negative Head and Neck Squamous Cell Carcinoma","author":"Antrobus","year":"2023"},{"issue":"47","key":"10.1016\/j.bioorg.2026.110048_bb0725","doi-asserted-by":"crossref","first-page":"E11138","DOI":"10.1073\/pnas.1801156115","article-title":"Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0730","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","article-title":"PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells","volume":"37","author":"Yin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0735","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110048_bb0740","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.biopha.2018.01.045","article-title":"Co-targeting poly (ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells","volume":"99","author":"Marijon","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110048_bb0745","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","article-title":"Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer","volume":"133","author":"Konstantinopoulos","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110048_bb0750","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13058-015-0534-y","article-title":"Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells","volume":"17","author":"Min","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0755","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/13543784.2022.2067527","article-title":"PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers","volume":"31","author":"Luo","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0760","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0765","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5483\/BMBRep.2024-0122","article-title":"Contribution of histone deacetylases (HDACs) to the regulation of histone and non-histone proteins: implications for fibrotic diseases","volume":"58","author":"Jang","year":"2025","journal-title":"BMB Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0770","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s12272-017-0998-7","article-title":"Therapeutic effects of histone deacetylase inhibitors on kidney disease","volume":"41","author":"Chun","year":"2018","journal-title":"Arch. Pharm. Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb0775","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-21-3729","article-title":"Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed\/refractory acute myeloid leukemia","volume":"28","author":"Baer","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb0780","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.7150\/ijbs.110947","article-title":"PARP inhibitor augments anti-tumor efficacy of DNMT inhibitor by inducing senescence in cholangiocarcinoma","volume":"21","author":"Wang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0785","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.jmedchem.8b01957","article-title":"Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer","volume":"62","author":"Shouksmith","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0790","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0795","first-page":"866","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat. Can."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110048_bb0800","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0805","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1021\/acs.jmedchem.8b01957","article-title":"Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer","volume":"62","author":"Shouksmith","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110048_bb0810","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110048_bb0815","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1158\/1541-7786.MCR-14-0173","article-title":"Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP","volume":"12","author":"Chao","year":"2014","journal-title":"Mol. Cancer Res."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110048_bb0820","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2174\/1568026619666190603092407","article-title":"Recent study of dual HDAC\/PARP inhibitor for the treatment of tumor","volume":"19","author":"Lu","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110048_bb0825","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1158\/1078-0432.CCR-22-3897","article-title":"A bifunctional PARP-HDAC inhibitor with activity in ewing sarcoma","volume":"29","author":"Ramos","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110048_bb0830","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tips.2007.08.005","article-title":"PARP-1 activation in the ERK signaling pathway","volume":"28","author":"Cohen-Armon","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0835","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.mam.2013.01.005","article-title":"PARP-1 and gene regulation: progress and puzzles","volume":"34","author":"Kraus","year":"2013","journal-title":"Mol. Asp. Med."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb0840","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/genes12020260","article-title":"Downregulation of cell cycle and checkpoint genes by class I HDAC inhibitors limits synergism with G2\/M checkpoint inhibitor MK-1775 in bladder cancer cells","volume":"12","author":"Hoffmann","year":"2021","journal-title":"Genes"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0845","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1389557522666220826141837","article-title":"The complex roles of DNA repair pathways, inhibitors, hyperthermia, and contact inhibition in cell cycle halts","volume":"23","author":"Ahmed","year":"2023","journal-title":"Mini-Rev. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110048_bb0850","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-15-2680","article-title":"Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2-triggered drug resistance","volume":"76","author":"Krumm","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0855","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3390\/jpm13091315","article-title":"Class I HDAC Inhibition Leads to a Downregulation of FANCD2 and RAD51, and the Eradication of Glioblastoma Cells","volume":"13","author":"Drzewiecka","year":"2023","journal-title":"J. Personal. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0860","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/genes14061295","article-title":"Histone deacetylases (HDAC) inhibitor\u2014valproic acid sensitizes human melanoma cells to dacarbazine and PARP inhibitor","volume":"14","author":"Drzewiecka","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.bioorg.2026.110048_bb0865","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.18632\/oncotarget.28278","article-title":"HDAC inhibitors suppress protein poly (ADP-ribosyl) ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs","volume":"13","author":"Valdez","year":"2022","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.110048_bb0870","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.939570","article-title":"Role of PARP inhibitors in glioblastoma and perceiving challenges as well as strategies for successful clinical development","volume":"13","author":"Bisht","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0875","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol. Oncol."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0880","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.3390\/ijms222413519","article-title":"An insight on novel molecular pathways in metastatic prostate cancer: a focus on DDR, MSI and AKT","volume":"22","author":"Mollica","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110048_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128821","article-title":"Design, synthesis and antitumor activity study of PARP-1\/HDAC dual targeting inhibitors","volume":"71","author":"Chi","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110048_bb0890","doi-asserted-by":"crossref","first-page":"1287444","DOI":"10.3389\/fonc.2023.1287444","article-title":"Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells","volume":"13","author":"Valdez","year":"2023","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110048_bb0895","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"6486","key":"10.1016\/j.bioorg.2026.110048_bb0900","doi-asserted-by":"crossref","first-page":"eaax6367","DOI":"10.1126\/science.aax6367","article-title":"Structural basis for allosteric PARP-1 retention on DNA breaks","volume":"368","author":"Zandarashvili","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110048_bb0905","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110048_bb0910","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.18632\/oncotarget.2154","article-title":"Histone deacetylase inhibitor treatment induces \u2018BRCAness\u2019 and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells","volume":"5","author":"Ha","year":"2014","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0915","first-page":"1849","article-title":"Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines","volume":"34","author":"Jasek","year":"2014","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bioorg.2026.110048_bb0920","series-title":"PARP Inhibitors for Cancer Therapy","first-page":"205","article-title":"Structure Based Design of PARP Inhibitors","author":"Canan","year":"2015"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0925","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, synthesis, and structure\u2013activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0930","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202406100","article-title":"Azetidine-Based Small-Molecule Targeted Anticancer Agents: Developments in the Last Decade (2015\u20132024)","volume":"10","author":"Pattanayak","year":"2025","journal-title":"ChemistrySelect"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0935","doi-asserted-by":"crossref","DOI":"10.1358\/dof.2020.45.6.3168440","article-title":"American Association for Cancer Research Virtual Annual Meeting I. April 27-28, 2020","volume":"45","author":"Toldra","year":"2020","journal-title":"Drugs Future"},{"issue":"19","key":"10.1016\/j.bioorg.2026.110048_bb0940","doi-asserted-by":"crossref","first-page":"16532","DOI":"10.1021\/acsomega.3c00222","article-title":"Single inhibitors versus dual inhibitors: role of HDAC in cancer","volume":"8","author":"Roy","year":"2023","journal-title":"ACS Omega"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0945","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/cells14241997","article-title":"Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy","volume":"14","author":"Hawash","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110048_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118743","article-title":"InhibitWin duo: Rational design and structural insights into dual PARP\/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation","volume":"309","author":"Elkafoury","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb0955","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/13543776.2020.1725470","article-title":"Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)","volume":"30","author":"Zhao","year":"2020","journal-title":"Expert Opin. Ther. Patents"},{"issue":"17","key":"10.1016\/j.bioorg.2026.110048_bb0960","doi-asserted-by":"crossref","first-page":"8977","DOI":"10.1021\/acs.jmedchem.0c00491","article-title":"Dual-target inhibitors based on HDACs: novel antitumor agents for cancer therapy","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110048_bb0965","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.2174\/0929867329666220922105615","article-title":"Multi-targeted HDAC inhibitors as anticancer agents: current status and future prospective","volume":"30","author":"Patel","year":"2023","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0970","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110048_bb0975","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5582\/ddt.2021.01100","article-title":"Dual targeting, a new strategy for novel PARP inhibitor discovery","volume":"15","author":"Wei","year":"2021","journal-title":"Drug Discov.Ther."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110048_bb0980","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER family and cancer: emerging molecular mechanisms and therapeutic targets","volume":"13","author":"Sergina","year":"2007","journal-title":"Trends Mol. Med."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110048_bb0985","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2165\/00003495-200767140-00006","article-title":"EGFR, HER2 and VEGF pathways: validated targets for cancer treatment","volume":"67","author":"Press","year":"2007","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb0990","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110048_bb0995","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/labinvest.3700466","article-title":"Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors","volume":"86","author":"Rubin","year":"2006","journal-title":"Lab. Investig."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb1000","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/pr.56.4.3","article-title":"Vascular endothelial growth factor and angiogenesis","volume":"56","author":"Hoeben","year":"2004","journal-title":"Pharmacol. Rev."},{"issue":"22","key":"10.1016\/j.bioorg.2026.110048_bb1005","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1016\/j.bmcl.2015.10.006","article-title":"Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase","volume":"25","author":"Peng","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110048_bb1010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.12.033","article-title":"Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC","volume":"109","author":"Peng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110048_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112073","article-title":"Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity","volume":"189","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"17","key":"10.1016\/j.bioorg.2026.110048_bb1020","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-aminopyridine-based and 2-aminopyrimidine-based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory solid tumors and hematological malignancies","volume":"67","author":"Saidahmatov","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110048_bb1025","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb1030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/stem.5530130408","article-title":"Mechanism of action of DNA topoisomerase inhibitors","volume":"13","author":"Binaschi","year":"1995","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110048_bb1035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.15430\/JCP.2015.20.2.85","article-title":"Dual inhibitors against topoisomerases and histone deacetylases","volume":"20","author":"Seo","year":"2015","journal-title":"J. Cancer Preven."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110048_bb1040","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1021\/jm200799p","article-title":"Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors","volume":"55","author":"Guerrant","year":"2012","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110048_bb1045","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acsmedchemlett.0c00014","article-title":"Design of first-in-class dual EZH2\/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells","volume":"11","author":"Romanelli","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110048_bb1050","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","article-title":"Six years (2012\u20132018) of researches on catalytic EZH2 inhibitors: The boom of the 2-pyridone compounds","volume":"18","author":"Fioravanti","year":"2018","journal-title":"Chem. Rec."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110048_bb1055","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","article-title":"Enhancer of zeste homolog 2 (EZH2) inhibitors","volume":"59","author":"Gulati","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bioorg.2026.110048_bb1060","doi-asserted-by":"crossref","first-page":"(3)","DOI":"10.1016\/j.celrep.2020.108638","article-title":"HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies","volume":"34","author":"Slaughter","year":"2021","journal-title":"Cell Rep."},{"issue":"14","key":"10.1016\/j.bioorg.2026.110048_bb1065","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1016\/j.bmc.2017.04.043","article-title":"Synthesis and evaluation of novel dual BRD4\/HDAC inhibitors","volume":"25","author":"Amemiya","year":"2017","journal-title":"Bioorg. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110048_bb1070","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acsmedchemlett.7b00172","article-title":"Design, synthesis, and biological evaluation of the first c-Met\/HDAC inhibitors based on pyridazinone derivatives","volume":"8","author":"Lu","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110048_bb1075","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejmech.2015.03.041","article-title":"Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis","volume":"95","author":"Xing","year":"2015","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826005845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:33:53Z","timestamp":1787675633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826005845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":215,"alternative-id":["S0045206826005845"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110048","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110048"}}